Literature DB >> 2295882

Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis.

R D Shahin1, M J Brennan, Z M Li, B D Meade, C R Manclark.   

Abstract

Immunization with the 69-kD outer membrane protein (OMP) of Bordetella pertussis protected neonatal mice against lethal respiratory challenge with B. pertussis 18323. Active immunization elicited a serum IgG anti-69-kD OMP response at the time of challenge, with IgG anti-69-kD OMP antibodies detected in bronchoalveolar lavage fluid after challenge. Intravenous administration of BPE8, a monoclonal IgG1 anti-69-kD OMP, also protected young mice against B. pertussis challenge. Intravenously injected BPE8 was detected in the lungs of mice at the time of aerosol challenge, suggesting that the presence of specific antibody in the lungs may mediate protection. Thus the 69-kD OMP of B. pertussis is a protective antigen in mice that elicits specific serum antibody that can transude to the lung. The 69-kD OMP was detected in a preparation of a Takeda acellular vaccine by immunoblot analysis and a serum antibody response to the 69-kD OMP was observed in 18-mo-old children boosted with this preparation of Japanese acellular vaccine. Our results demonstrate that the B. pertussis 69-kD OMP is a protective antigen in animals, is immunogenic in humans, and is present in a preparation of acellular pertussis vaccine that is widely used in Japan. These findings indicate that the 69-kD OMP should be seriously considered as a candidate for inclusion in new formulations of antigenically defined acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295882      PMCID: PMC2187668          DOI: 10.1084/jem.171.1.63

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  VACCINATION against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley.

Authors: 
Journal:  Br Med J       Date:  1956-08-25

2.  Evaluation of Bordetella bronchiseptica vaccines in specific-pathogen-free piglets with bacterial cell surface antigens in enzyme-linked immunosorbent assay.

Authors:  P Novotny; M Kobisch; K Cownley; A P Chubb; J A Montaraz
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

3.  Transfer of humoral secretory and cellular immunity from mother to offspring.

Authors:  J P Kraehenbuhl; C Bron; B Sordat
Journal:  Curr Top Pathol       Date:  1979

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Immune response to the B oligomer of pertussis toxin.

Authors:  J L Arciniega; D L Burns; E Garcia-Ortigoza; C R Manclark
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Identification of a 68-kilodalton protective protein antigen from Bordetella bronchiseptica.

Authors:  J A Montaraz; P Novotny; J Ivanyi
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

7.  Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis.

Authors:  M J Brennan; Z M Li; J L Cowell; M E Bisher; A C Steven; P Novotny; C R Manclark
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

8.  Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination.

Authors:  M G Thomas; K Redhead; H P Lambert
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

9.  Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis.

Authors:  I G Charles; G Dougan; D Pickard; S Chatfield; M Smith; P Novotny; P Morrissey; N F Fairweather
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.

Authors:  C L Cody; L J Baraff; J D Cherry; S M Marcy; C R Manclark
Journal:  Pediatrics       Date:  1981-11       Impact factor: 7.124

View more
  43 in total

1.  Maternal immunity provides protection against pertussis in newborn piglets.

Authors:  Shokrollah Elahi; Rachelle M Buchanan; Lorne A Babiuk; Volker Gerdts
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.

Authors:  J W Petersen; P H Ibsen; K Hasløv; I Heron
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

3.  Infection of newborn piglets with Bordetella pertussis: a new model for pertussis.

Authors:  S Elahi; R Brownlie; J Korzeniowski; R Buchanan; B O'Connor; M S Peppler; S A Halperin; S F Lee; L A Babiuk; V Gerdts
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.

Authors:  L Nencioni; M Pizza; M Bugnoli; T De Magistris; A Di Tommaso; F Giovannoni; R Manetti; I Marsili; G Matteucci; D Nucci
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

6.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection.

Authors:  R D Shahin; D F Amsbaugh; M F Leef
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide.

Authors:  R D Shahin; J Hamel; M F Leef; B R Brodeur
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 9.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

10.  Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.

Authors:  Yinghua Xu; Yaying Wang; Yajun Tan; Huajie Zhang; Lijie Wu; Lichan Wang; Qiming Hou; Shumin Zhang
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.